ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Two biotech companies have each raised tens of millions in series A funding to develop antibody-drug conjugates (ADCs). San Diego–based Adcentrx Therapeutics will receive $50 million for cancer-fighting ADCs that use what company founder Hui Li calls a proprietary conjugation platform. Copenhagen-based Adcendo will receive $62 million to advance its ADCs, including one that targets a novel cancer marker—a collagen-scavenging protein called uPARAP/Endo180.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X